# CEPHEUS (NCT03652064)

> A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03652064
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Janssen Research & Development, LLC
- Conditions: Multiple Myeloma
- Interventions: Daratumumab; Bortezomib; Lenalidomide; Dexamethasone
- Enrollment: 395
- Primary outcome: Primary Analysis: Overall Minimal Residual Disease (MRD) Negative Rate
- Primary outcome: Final Progression-Free Survival (PFS) Analysis : Overall Minimal Residual Disease (MRD) Negative Rate

## Questions raised in the commentary

_Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice._

The commentary discusses CEPHEUS as a comparison of daratumumab plus VRd with VRd in newly diagnosed, transplant-ineligible or transplant-deferred myeloma, including MRD depth and durability, progression-free and overall survival, and longer-term follow-up. It also covers comparisons with IMROZ, quality of life, frailty, age and transplant selection, and treatment burden and cost. Speakers raise questions about maintenance duration, whether stopping should be guided by MRD rather than a fixed time, and how to weigh infection, neuropathy and other safety concerns.

## Indexed commentary on CEPHEUS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 94
- YouTube: 87
- Podcasts: 43
- X videos: 4
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=cepheus-nct03652064

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03652064", "email": "<work email>"}; the inbox owner confirms by the emailed link.